Insight
Ilya Tsimafeyeu
Ilya Tsimafeyeu/bucare.org

Ilya Tsimafeyeu Presented Phase 2 SBRT Trial in Oligoprogressive Urothelial Cancer on Avelumab at ASCO 2025

Ilya Tsimafeyeu, Director at the Bureau of Cancer Re­search, shared a post on Facebook:

“Our randomized phase 2 study of stereotactic body radiation therapy in patients with oligoprogressive metastatic urothelial cancer receiving maintenance avelumab was announced at the Trials in Progress session at ASCO25.”

Urothelial Cancer

More posts featuring Ilya Tsimafeyeu on OncoDaily.

Read OncoDaily’s Special Articles about ASCO 2025:

Highlights from ASCO 2025 Day 1

Highlights from ASCO 2025 Day 2

Highlights from ASCO 2025 Day 3

Highlights from ASCO 2025 Day 4

Urothelial Cancer

ASCO ASCO 2025 ASCO25 Avelumab Bureau of Cancer Re­search cancer Ilya Tsimafeyeu Oligoprogressive Urothelial Cancer OncoDaily Oncology radiation therapy